Search for: "GENENTECH, INC." Results 241 - 260 of 469
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
15 Dec 2011, 9:00 am by The Docket Navigator
Genentech Inc., et. al., 2-11-cv-06519 (CACD December 9, 2011, Order) (Pfaelzer, J.).The magistrate judge recommended denying plaintiff's motion to dismiss defendant's inequitable conduct claims and rejected plaintiff's argument that Therasense, Inc. v. [read post]
12 Dec 2011, 1:37 pm by Rantanen
Genentech, Inc., 549 U.S. 118 (2007)….? [read post]
8 Dec 2011, 9:59 pm by Patent Docs
Genentech, Inc., 549 U.S. 118 (2007), that petitioners who have been indisputably deterred by Myriad's "active enforcement" of its patent rights nonetheless lack standing to challenge those patents absent... [read post]
8 Dec 2011, 2:50 pm by Matt Osenga
Genentech, Inc., 549 U.S. 118 (2007), that petitioners who have been indisputably deterred by Myriad’s “active enforcement” of its patent rights nonetheless lack standing to challenge those patents absent evidence that they have been personally and directly threatened with an infringement action? [read post]
5 Dec 2011, 1:41 pm by Ed Wallis
Specifically as to that suit: Ron Leuty wrote in a San Francisco (CA) Business Times (12/2, Subscription Publication) blog posting that “Genentech Inc. will pay $20 million to settle a whistleblower lawsuit around off-label marketing of the cancer-fighting drug Rituxan. [read post]
4 Nov 2011, 10:44 pm
Genentech, Inc., 927 F.2d 1565, 1580 (Fed. [read post]
30 Sep 2011, 1:10 pm
" PTI appealed, whereupon the CAFC, citing the Supreme Court's 2007 MedImmune, Inc. v. [read post]
4 Aug 2011, 9:59 pm by Patent Docs
Genentech, Inc., 549 U.S. 764, 777 (2007) (Thomas, J., dissenting), citing Aetna... [read post]
3 Aug 2011, 1:24 pm
” (See MedImmune v Genentech, 549 U.S. 118, at 127 (Sup Ct, 2007)), the Court moved to consider the main issue at play in the case: patentable subject-matter. [read post]
31 Jul 2011, 9:28 pm
Genentech, Inc., 549 U.S. 118, 127 (2007). [read post]
15 Jul 2011, 7:41 am by Cara Disisto
/Genentech Inc. (153), Advanced Cardiovascular Systems (Abbott Vascular) (142), and Agilent Technologies (129). [read post]